Sucharu Prakash, Director of Quality Services at Texas Oncology, shared on LinkedIn:
“Another powerful reminder of why genomic testing is essential in oncology!
The FDA has approved talazoparib + enzalutamide for patients with metastatic androgen pathway modulation sensitive prostate cancer harboring homologous recombination repair (HRR) gene mutations.
The approval is supported by the Phase 3 TALAPRO-3 trial (n=599), which demonstrated a significant improvement in radiographic progression-free survival:
- HR 0.48 (95% CI 0.36–0.65; p<0.0001)
- Median rPFS was not reached with talazoparib + enzalutamide versus 45.8 months with placebo + enzalutamide.
Importantly, eligible patients were identified through genomic testing of tumor tissue or circulating tumor DNA.
But beyond the approval itself, there is a much bigger message.
If we don’t test, we won’t find the mutations. And if we don’t find the mutations, patients may miss opportunities for potentially life-changing targeted treatments.
This is exactly why I believe CGP and germline testing should become routine parts of cancer care, not just in prostate cancer, but across all cancer types.
We need to identify actionable alterations early, understand inherited cancer predisposition, and make sure our patients have access to the treatments and clinical trials that may benefit them.
This requires a coordinated effort involving physicians, advanced practice providers, nurses, laboratories, genetic counselors, pharmacists, and our entire oncology care team- across Texas Oncology The US Oncology Network and other practices.
Precision medicine cannot deliver on its promise if we don’t identify the patients who stand to benefit.
Test early. Test comprehensively. Don’t miss the mutation, and don’t miss the opportunity to treat it.”
You can also read:
TALAPRO-3 at ESMO 2026: Prognostic Utility of ctDNA Tumour Fraction in mCSPC
